| Literature DB >> 31191573 |
Georgianna K Oguis1, Edward K Gilding1, Mark A Jackson1, David J Craik1.
Abstract
The perennial leguminous herb Clitoria ternatea (butterfly pea) has attracted significant interest based on its agricultural and medical applications, which range from use as a fodder and nitrogen fixing crop, to applications in food coloring and cosmetics, traditional medicine and as a source of an eco-friendly insecticide. In this article we provide a broad multidisciplinary review that includes descriptions of the physical appearance, distribution, taxonomy, habitat, growth and propagation, phytochemical composition and applications of this plant. Notable amongst its repertoire of chemical components are anthocyanins which give C. ternatea flowers their characteristic blue color, and cyclotides, ultra-stable macrocyclic peptides that are present in all tissues of this plant. The latter are potent insecticidal molecules and are implicated as the bioactive agents in a plant extract used commercially as an insecticide. We include a description of the genetic origin of these peptides, which interestingly involve the co-option of an ancestral albumin gene to produce the cyclotide precursor protein. The biosynthesis step in which the cyclic peptide backbone is formed involves an asparaginyl endopeptidase, of which in C. ternatea is known as butelase-1. This enzyme is highly efficient in peptide ligation and has been the focus of many recent studies on peptide ligation and cyclization for biotechnological applications. The article concludes with some suggestions for future studies on this plant, including the need to explore possible synergies between the various peptidic and non-peptidic phytochemicals.Entities:
Keywords: anthocyanins; butelase; forage crop; medicinal plant; organic pesticide; peptides
Year: 2019 PMID: 31191573 PMCID: PMC6546959 DOI: 10.3389/fpls.2019.00645
Source DB: PubMed Journal: Front Plant Sci ISSN: 1664-462X Impact factor: 5.753
FIGURE 1Timeline of the key studies and milestones on Clitoria ternatea research from the 1950s to the present. The biological (blue) and biochemical (purple) studies pursued from the 1950s to early 1970s characterized the properties of roots and seeds. Toward the end of the 1970s, researchers began to isolate and characterize the phytochemical compounds from C. ternatea. Ternatins, the anthocyanins that render C. ternatea its vivid blue color, were first isolated in 1985; and the structure of the largest of the ternatins, ternatin A1, was characterized in 1989. Further isolation and characterization of the ternatins in C. ternatea led to the elucidation of the ternatin biosynthetic pathway in 1998. Parallel to the studies that characterized the phytochemical composition of C. ternatea, were agricultural studies that evaluated C. ternatea as a forage and fodder crop. A series of field studies in Queensland, Australia lead the development and eventual release of the C. ternatea Milgarra cultivar in 1991. From 2001 to the present, studies have been determining the pharmacological activities and biological activities of C. ternatea extracts. In 2011, cyclotides, the circular insecticidal molecules which can also be used as scaffolds for peptide-based therapeutics, were discovered in C. ternatea. While cyclotides had previously been characterized in other angiosperm species, C. ternatea is to date, the only legume that is known to produce them. In 2014, butelase-1, the ligase that facilitates cyclization in C. ternatea cyclotides, was discovered and characterized. Cyclotides and the auxiliary enzymes, have applications both in modern medicine and agriculture. In 2017, Sero-X® an eco-friendly insecticide made from C. ternatea extracts was registered for commercial use in Australia.
Milestones in Clitoria ternatea studies.
| Years | Milestones | References |
|---|---|---|
| 1954 | Seed fatty acid composition analyzed | |
| 1962 | Root diuretic properties screened | |
| 1967 | Phytochemical composition of seeds analysis | |
| 1967–1968 | Germination studies and | |
| 1974 | Nodulation pattern characterized | |
| 1976 | Kaempferol-glycosides in leaves isolated | |
| 1980–1990 | Forage and grain crop properties evaluated | |
| 1985 | Ternatins isolated from flowers | |
| 1989 | Structure of Ternatin A1 determined | |
| 1991 | Milgarra cultivar registered in Australia | |
| 1998 | Ternatin biosynthetic pathway determined | |
| 2000 | Pharmacological activities of the extracts determined | |
| 2004 | Antimicrobial properties characterized | |
| 2011 | Cyclotides in | |
| 2014 | Butelase discovered | |
| 2017 | Sero-X® registered | Innovate Ag, 20181 |
FIGURE 2Clitoria ternatea (A) flower, (B) pods, (C) leaves, and (D) roots with nodules. The C. ternatea flower consists of the stamen (st), pistil (p), sepals (sp), and corollae. The corollae consist of five petals: one banner (b), two wings (w) and two keels (k). C. ternatea has pinnate compound leaves, flat and pointed pods and roots that produce nodules (n).
FIGURE 3Distribution of Clitoria subgenus Clitoria species adapted from Fantz, 1977. Points of occurrence are approximate. Map data from Openstreetmap.org. Symbols represent: ◼ C. biflora, □ C. heterophylla, Δ C. kaessneri, • C. lasciva, + C. ternatea.
Summary of published Clitoria ternatea in vitro propagation studies.
| Hormone concentrations | Basal medium | Explants used | Results | References |
|---|---|---|---|---|
| – | MS | Mature embryo | Callus on seedling root | |
| 0.1 mg/L KN | MS | Mature embryo | Callus on seedling lateral root | |
| 0.5 mg/L KN | MS | Mature embryo | Callus on seedling root and hypocotyl; embryogenesis | |
| 0.5 mg/L KN + 0.5 mg/L IAA | MS | Mature embryo | Callus on seedling root; embryogenesis | |
| 1.12 mg/L BAP + 2.2 or 4.4 mg/L 2,4-D | MS | Excised root segments from aseptic seedlings | Organogenic callus | |
| 2.0 mg/L BAP + 1.0 mg/L NAA | DKW | Leaf explants from aseptic seedlings | Callus formation | |
| 1.0 mg/L NAA + 0.5 mg/L BAP + 40 mg/L 2iP | MS | Aseptic leaf explants encapsulated using 3% sodium alginate | Callus formation | |
| 0.56 - 2.25 mg/L BAP + 0.37 mg/L NAA | MS | Calli derived from excised root segments | Shoot proliferation | |
| – | ½ MS | Isolated shoot buds (0.2–0.5 cm in length) from mature embryo | Shoot proliferation | |
| 0.1–0.5 mg/L BAP | MS | Isolated shoot buds (0.2–0.5 cm in length) from mature embryo | Shoot proliferation | |
| 2.5 mg/L BAP + 0.25 mg/L NAA | MS | Axillary buds | Shoot proliferation | |
| 2 mg/L BAP + 0.25 mg/L NAA | Semisolid MS | Nodal explants | Shoot proliferation | |
| 1.12 mg/L BAP | MS | Nodal explants | Shoot proliferation | |
| 2.0 mg/L BAP | MS | Shoot tip, node, cotyledonary node explants | Shoot proliferation | |
| 0.5 mg/L GA | MS | Shoot tip, node, cotyledonary node explants | Shoot elongation | |
| 1.0 mg/L BAP | DKW | Leaf explants from aseptic seedlings | Shoot proliferation | |
| 4.5 mg/L BAP + 0.37 mg/L NAA | MS | Excised root segments from aseptic seedlings | Shoot proliferation | |
| 0.02 mg/L TDZ; 0.2 mg/L TDZ | MS | Cotyledonary node; nodal explants | Shoot proliferation | |
| 0.1–0.5 mg/L IBA | MS | Isolated shoots (2.0–5.0 cm in length) proliferated from mature embryo | Rooting | |
| 0.1–0.5 mg/L IAA | MS | Isolated shoots (2.0–5.0 cm in length) proliferated from mature embryo | Rooting | |
| 0.25 mg/L NAA | ½ MS (2% suc) | Directly regenerated shoots from nodal explants | Rooting | |
| 1.0 mg/L IBA | ½ MS | Shoots derived from organogenic calli | Rooting | |
| 0.2–0.4 mg/L IBA | ½ MS | Directly regenerated elongated shoots from nodal, cotyledonary nood and shoot tips | Rooting | |
| 0.56 mg/L NAA | MS | Directly regenerated shoots from axillary buds | Rooting | |
| Dipping in 250 mg/L IBA for 30 min | Soilrite | Elongated shoots | Rooting ( | |
| 2.0 mg/L NAA | DKW | Leaf explants from aseptic seedlings | Rooting | |
Animal studies and clinical trial demonstrating the pharmacological activities of Clitoria ternatea extracts.
| Tissue | Extraction solvent | Dosage (mg extract/kg body weight) | Administration | Experimental animals | Results | References |
|---|---|---|---|---|---|---|
| Roots | Ethanol | 16 or 19 | Single, oral | Dogs | No diuretic and natriuretic effects | |
| Roots | Ethanol | 4 or 6 | Single, intravenous | Dogs | Increase in Na+ and K+, and decrease in Cl- in the urine; no change in urine volume | |
| Roots, aerial tissues | Ethanol | 300 or 500 | Daily for 7 d, oral | Wistar rats | Attenuated electric shock-induced amnesia; increase in acetylcholine content in the brain | |
| Roots | Water | 50 or 100 | Daily for 30 days, oral | 7-day old Wistar rats | Improved memory retention and spatial learning 48 h and 30 days post treatment | |
| Roots | Methanol | 100, 200, or 400 | Single, oral | Albino mice or Wistar rats | Nootropic, anxiolytic, antidepressant, anticonvulsant and anti-stress activities | |
| Roots | Water | 100 | Daily for 30 days, oral | neonatal and adult Wistar rats | Higher hippocampal acetylcholine content in treated animals than their corresponding age group controls | |
| Roots | Water | 100 | Daily for 30 days, oral | Adult Wistar rats | Increase in memory retention and spatial learning; increase in dendritic arborization | |
| Leaves | Ethanol | 200 or 400 | Daily for 14 days, oral | Sprague Dawley rats | Decrease in acetylcholinesterase activity; decrease nitric oxide and lipid peroxide levels; increase in catalase, superoxide dismutase and glutathione levels | |
| Whole plant | – | 3 g/kg | Fed for 60 days | Wistar rats | Protection of hippocampal cells through autophagy reduction | |
| Roots | Methanol | 200 or 400 | Single, oral | Wistar rats | Reduction in carrageenin-induced paw oedema and inhibition acetic acid-induced vascular permeability | |
| Roots | Methanol | 200, 300, or 400 | Single, oral | Wistar rats | Reduction body temperature reduction | |
| Leaves | Water, ethanol and petroleum ether | 100–400 | Single, oral | Wistar rats | Reduction in carrageenin-induced paw oedema; displayed analgesic activity determined by the tail flick method | |
| Roots | Ethanol | 100–150 | Single, Intraperitoneal | Albino mice and Wistar rats | Decrease in leukocytosis and eosinophilia and inhibition of anaphylaxis in Wistar rats; protection from mast cell degranulation in albino mice | |
| Flowers | Ethanol | 400 | Single, oral | Guinea pigs and albino mice | Reduction in histamine-induced dyspnoea in Guinea pigs; Reduction in coughing, lung inflammation, and decrease in white blood cell counts, interleukin and immunoglobulin G1 levels in albino mice | |
| Leaves | Ethanol | 400 | Daily for 28 days, oral | Wistar rats | Reduction in the levels blood glucose, insulin, glycosylated hemoglobin, urea, creatinine and liver marker enzymes | |
| Seeds, roots | Hydroalcohol | 500 | Single, oral | Sprague Dawley rats | Reduction in total serum cholesterol, triglyceride and very low density lipoprotein levels in rats with Poloxamer 407-induced hyperlipidemia | |
| Seeds, roots | Hydroalcohol | 500 | Daily for 7 days, oral | Sprague Dawley rats | Reduction in triglyceride and cholesterol levels | |
| Flowers | Methanol | 50 | Every other day for 24 days, oral | Male Swiss albino mice | Reduction in expression or release of enzymes, receptors or molecules implicated in inflammatory responses | |
| Flowers∗ | Aqueous | 1–2 g in 400 mL water | Single, oral | Healthy adult males | Increase in plasma antioxidant capacity; decrease in postprandial sucrose and insulin levels; enhancement of postprandial antioxidant status | |
In vitro studies demonstrating the pharmacological properties of Clitoria ternatea extract.
| Extract | Concentration | Results | References | |
|---|---|---|---|---|
| Ethanolic floral extract | 2.5–10 mg/mL | Extract addition to isolated adult goat tracheal tissue and guinea pig ileum dosed with histamine | Inhibition of histamine-induced contraction | |
| Methanolic leaf extract | Six 2-fold dilution of 50 μg/ml | Hyaluronidase inhibition assay | Significant inhibition; IC50 = 18.08 ± 0.46 μg/ml | |
| Methanolic leaf extract | Six 2-fold dilution of 50 μg/ml | Matrix metalloproteinase-1 inhibition assay (MMP-1) | Significant inhibition of MMP-1 | |
| Aqueous floral extract | 400 μg/mL | Hemolytic and oxidation assays on canine erythrocytes | 60% erythrocyte hemolysis protection after 6 h; decrease in lipid peroxidation and protein oxidation and increase in glutathione levels | |
| Aqueous floral extract | 1 and 2% (w/v) extract | Porcine α-amylase assay | Significant α-amylase inhibition, reduction in glucose release, hydrolysis index and glycemic index | |
Anthelmintic and insecticidal activities of Clitoria ternatea.
| Biological activity | Organism | Results | References |
|---|---|---|---|
| Anthelmintic | 27 | ||
| Methanolic leaf extract inhibited 93% of eggs from hatching | |||
| Significant toxicity of root extract on larvae | |||
| Ethanolic root extract increased mortality rate and number or paralyzed worms at 50 mg/mL | |||
| Ethanolic and aqueous extract increased mortality and induced worm paralysis at 100 mg/mL | |||
| Insecticidal | 1% w/w finotin application resulted to 100% larval mortality | ||
| 5% w/w finotin application resulted to 100% larval mortality | |||
| Cter M cyclotide retarded larval growth in a dose dependent manner; 1 μmol/g diet induced larval mortality | |||
| 1–2% v/v oil-based extract resulted in larval mortality and reduced oviposition and larval feeding; detrimental effects against beneficial insects were not observed | |||
Antimicrobial activities of Clitoria ternatea.
| Biological activity | Organism | Extract/component | References |
|---|---|---|---|
| Antibacterial | Ethanolic and aqueous leaf and callus extract | ||
| Ethanolic and aqueous leaf and callus extract | |||
| Ethanolic leaf and callus extract | |||
| Cliotides T1, T4, T7, T15, T16, T19, and T20 | |||
| Cliotides T1 and T4 | |||
| 14.3 kDa seed protein | |||
| Cliotides T1 and T4 | |||
| Ethanolic leaf and callus extract; ultrasound-assisted aqueous leaf and petal extract | |||
| Ethanolic leaf and callus extract | |||
| Ethanolic leaf and callus extract, aqueous leaf extract | |||
| Ethanolic leaf and callus extract | |||
| Finotin | |||
| Antifungal | 14.3 kDa seed protein | ||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein; methanolic leaf extract | |||
| Finotin | |||
| Finotin | |||
| Finotin | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
| 50% aqueous ethanolic leaf extract | |||
| Finotin | |||
| Finotin | |||
| Finotin | |||
| Finotin | |||
| 14.3 kDa seed protein | |||
| 14.3 kDa seed protein | |||
Flavonol and anthocyanin content of Clitoria ternatea.
| Compound name | Tissue isolated | References | |
|---|---|---|---|
| Flavonols | Kaempferol; | Blue flowers | |
| Kaempferol 3-glucoside; | Leaves, blue, mauve, and white flowers | ||
| Kaempferol 3-rutinoside; | Leaves, blue, mauve, and white flowers | ||
| Kaempferol-3- | Leaves | ||
| Kaempferol 3- | Blue, mauve, and white flowers | ||
| Quercetin | Blue flowers | ||
| Quercetin 3-glucoside | |||
| Quercetin 3- | Blue, mauve, and white flowers | ||
| Myricetin 3-neohesperidoside; | Blue, mauve, and white flowers | ||
| Myricetin 3-(2G-rhamnosylrutinoside) | Blue, mauve, and white flowers | ||
| Myricetin 3- | Blue and white flowers | ||
| Anthocyanins | Ternatin A1, A2, B1, D1 | Blue flowers | |
| Ternatin B2, D2 | Blue flowers | ||
| Ternatin A3, B3-B4 | Blue flowers | ||
| Ternatin C1- C5, D3 | Blue flowers | ||
| Preternatin A3 and C4 (demalonylated analogs) | Mostly from young flowers | ||
| Delphinidin 3- | Mauve flowers | ||
| 3- | Blue flowers | ||
FIGURE 4Proposed ternatin biosynthetic pathway. Adapted from Terahara et al. (1998). Beginning with ternatin C5 (PubChem CID 10843319), ternatin A1 (PubChem CID 16173494) can be produced through the addition of four p-coumaroyl (C) and four glucosyl moieties (G) at the 3′ sidechain (in blue) and 5′ sidechain (in orange). The other ternatins are products of the intermediate steps.
FIGURE 5Graphical representations of C. ternatea cyclotide structure and diversity. (A) Topological depiction of Cter M displaying the position and threading of disulfide bonds. (B) Diversity of residues at non-cystine positions of 74 sequence defined C. ternatea cyclotides. (C) Loop length diversity and disulfide connectivity map of C. ternatea cyclotides.
Cyclotides in Clitoria ternatea.
| Cyclotide | Other name | Sequence | References |
|---|---|---|---|
| Cliotide T1 | GIPCGESCVFIPCITGAIGCSCKSKVCYRN | ||
| Cliotide T2 | GEFLKCGESCVQGECYTPGCSCDWPICKKN | ||
| Cliotide T4 | Cter P | GIPCGESCVFIPCITAAIGCSCKSKVCYRN | |
| Cliotide T6 | SIPCGESCVYIPCLTTIVGCSCKNSVCYSN | ||
| Cliotide T8 | GIPCGESCVFIPCISSVVGCSCKSKVCYNN | ||
| Cliotide T9 | GIPCGESCVFIPCITTVVGCSCKNKVCYNN | ||
| Cliotide T10 | Cter 27 | GIPCGESCVYIPCTVTALLGCSCKDKVCYKN | |
| Cliotide T11 | Cter 21 | GIPCGESCVFIPCTITALLGCSCKDKVCYKN | |
| Cliotide T12 | GIPCGESCVFIPCITGAIGCSCKSKVCYRD | ||
| Cliotide T13 | Cter 23 | DTTPCGESCVWIPCVSSIVGCSCQNKVCYQN | |
| Cliotide T14 | DTIPCGESCVWIPCISSILGCSCKDKVCYHN | ||
| Cliotide T15 | Cter24 | GLPICGETCFKTKCYTKGCSCSYPVCKRN | |
| Cliotide T16 | GSVIGCGETCLRGRCYTPGCTCDHGICKKN | ||
| Cliotide T17 | GTVPCGESCVFIPCITGIAGCSCKNKVCYLN | ||
| Cliotide T18 | Cter 6 | GLPICGETCFTGTCYTPGCTCSYPVCKKN | |
| Cliotide T19a | Cter26 | GSVIKCGESCLLGKCYTPGCTCSRPICKKN | |
| Cliotide T19b | GSVIKCGESCLLGKCYTPGCTCSRPICKKD | ||
| Cliotide T20 | GSAIRCGESCLLGKCYTPGCTCDRPICKKN | ||
| Cliotide T21 | Cter 17 | DLQCAETCVHSPCIGPCYCKHGLICYRN | |
| Cliotide T22α | ARIPCGESCVWIPCTITALVGCACHEKVCYKS | ||
| Cliotide T23∗ | GFPCGESCVFIPCTVTALLGCSCKDKVCYKN | ||
| Cliotide T25∗ | GSIRCGERCLLGRCHRPGCTCVRRICRRN | ||
| Cliotide T26∗ | GFICGESCVYIPCITALLGCSCSNQICSKN | ||
| Cliotide T27∗ | GVIPCGESCVFIPCITGAIGCSCKSKVCYRN | ||
| Cliotide T30∗ | GDPLKCGESCFAGKCYTPGCTCSRPICKKN | ||
| Cliotide T31∗ | GDPLKCGESCFAGKCYTPGCTCDRPICKKN | ||
| Cliotide T32∗ | GDLFKCGETCFGGTCYTPGCSCDYPICKNN | ||
| Cliotide T37α | VDGFCLETCVILPCFSSVAGCYCHGSTCMRG | ||
| Cliotide T38α | KIPCGESCVWIPCFTSAFGCYCQSKVCYHS | ||
| Cliotide T42∗ | DIPCGSTCLHVKCIPPCYCKNKVLCYRN | ||
| Cliotide T47β | XIPCGESCVYLPCLTTIVGCSCKNNVCYTN | ||
| Cliotide T48β | XCGESCVFLPCFIIPGCSCKDKVCYLN | ||
| Cliotide T49β | NSAFCGETCVLGTCYTPDCSCKAVVCX | ||
| Cliotide T50β | GVSWICDQTCLMQGKCYRSGCTCDRPX | ||
| Cliotide T51β | GVPLCGETCFMGSCYTPGCSCDAVX | ||
| Cliotide T52β | GDALKCGETCFGGTCYTPGCSX | ||
| Cliotide T53β | GSSIVTCGETCLRGRCYTPGCX | ||
| Cter 1∗ | Cliotide T35 | GLPICGETCFGGTCNTPNCVCDPWPICTNN | |
| Cter 10∗ | Cliotide T34 | SYIPCGESCVYIPCTVTALLGCSCSNKVCYKN | |
| Cter 11∗ | Cliotide T24 | GSIRCGERCLLGRCHRPGCTCIRRICRRN | |
| Cter 12∗ | NTAFCGETCVLGTCYTPDCSCKAVVCIKN | ||
| Cter 13∗ | GSAIRCGERCLLGRCHRPGCTCIRRICRRN | ||
| Cter 14∗ | Cliotide T40 | GIPCGESCVFIPCTITALLGCSCKSKVCYKN | |
| Cter 15∗ | GIPCGESCVFIPCTVTALLGCSCKSKVCYKN | ||
| Cter 16∗ | Cliotide T28 | GGSIPCGESCVFLPCFLPGCSCKSSVCYLN | |
| Cter 18∗ | Cliotide T43 | DLICSSTCLHTPCKASVCYCKNAVCYKN | |
| Cter 19∗ | SIPCGESCVYIPCLTTIVGCSCKSNVCYSN | ||
| Cter 2∗ | Cliotide T29 | GDPLKCGESCFAGKCYTPGCTCEYPICMNN | |
| Cter 20∗ | GVIPCGESCVYLPCLTTIVGCSCKNNVCYTN | ||
| Cter 22∗ | NTAFCGETCVLGTCYTPDCSCTAIVCIKN | ||
| Cter 25∗ | Cliotide T41 | GNPIVCGETCFFQKCYTPGCSCDAVICTNN | |
| Cter 28∗ | Cliotide T36 | GVIPCGESCVWIPCISAAIGCSCKKNVCYRN | |
| Cter 29∗ | Cliotide T44 | GALCDERCTYVPCISAARGCSCNIHRVCSMN | |
| Cter 3∗ | GAFCGETCVLGTCYTPDCSCKAVVCIKN | ||
| Cter 30∗ | Cliotide T45 | GFPICGETCFKTKCYTPGCSCSYPVCKKN | |
| Cter 31∗ | Cliotide T46 | DLQCAETCVHSPCIGPCYCKHGVICYKN | |
| Cter 32∗ | KIPCGESCVWIPCISSILGCSCKDKVCYHN | ||
| Cter 33∗ | GDLFKCGETCFGGTCYTPGCSCDYPICKKN | ||
| Cter 34∗ | Cliotide T33 | GFNSCSEACVYLPCFSKGCSCFKRQCYKN | |
| Cter 35∗ | GAFCGETCVLGTCYTPGCSCAPVICLNN | ||
| Cter 36∗ | GSPTCGETCFGGTCYTPNCVCDPWPICTKN | ||
| Cter 37∗ | GSPTCGETCFGGTCYTPGCVCDPWPICTKN | ||
| Cter 4∗ | Cliotide T39 | GDPLACGETCFGGTCYTPGCVCDPWPICTKN | |
| Cter 5∗ | GEFLKCGESCVQGECYTPGCSCDYPICKNN | ||
| Cter 7∗ | GDPFKCGESCFAGKCYTPGCTCEYPICMNN | ||
| Cter 8∗ | GSAFCGETCVLGTCYTPDCSCKAVVCIKN | ||
| Cter 9∗ | GIPCGESCVYIPCTVTALLGCSCRDKVCYKN | ||
| Cter A | GVIPCGESCVFIPCISTVIGCSCKNKVCYRN | ||
| Cter B | GVPCAESCVWIPCTVTALLGCSCKDKVCYLN | ||
| Cter C | GVPCAESCVWIPCTVTALLGCSCKDKVCYLD | ||
| Cter D | GIPCAESCVWIPCTVTALLGCSCKDKVCYLN | ||
| Cter E | GIPCAESCVWIPCTVTALLGCSCKDKVCYLD | ||
| Cter F | GIPCGESCVFIPCISSVVGCSCKSKVCYLD | ||
| Cter G | GLPCGESCVFIPCITTVVGCSCKNKVCYNN | ||
| Cter H | GLPCGESCVFIPCITTVVGCSCKNKVCYND | ||
| Cter I | GTVPCGESCVFIPCITGIAGCSCKNKVCYIN | ||
| Cter J | GTVPCGESCVFIPCITGIAGCSCKNKVCYID | ||
| Cter K | HEPCGESCVFIPCITTVVGCSCKNKVCYN | ||
| Cter L | HEPCGESCVFIPCITTVVGCSCKNKVCYD | ||
| Cter M | Cliotide T3 | GLPTCGETCTLGTCYVPDCSCSWPICMKN | |
| Cter N | GSAFCGETCVLGTCYTPDCSCTALVCLKN | ||
| Cter O | GIPCGESCVFIPCITGIAGCSCKSKVCYRN | ||
| Cter Q | Cliotide T5 | GIPCGESCVFIPCISTVIGCSCKNKVCYRN | |
| Cter R | Cliotide T7 | GIPCGESCVFIPCTVTALLGCSCKDKVCYKN | |
| Cterneg_C1α | GSPLLRGETCVLQTCYTPGCSCTIAICLNN | ||
Characteristics of cyclotide gene precursors.
| Taxonomy | Precursor characters | ||||
|---|---|---|---|---|---|
| Family | Exemplary species | Signal peptide to cyclotide N-terminal junction present | N-terminal pre- sequence present | Multimeric or singleton cyclotide domains present | C-terminal sequence type |
| Cucurbitaceae | N | Y | Multimeric | None, except final repeat is acyclic | |
| Fabaceae | Y | N | Singleton | Linker and albumin-1 a-chain domain | |
| Rubiaceae | N | Y | Both | Short, ∼5 aa | |
| Solanaceae | N | Y | Singleton | Short, ∼5 aa | |
| Violaceae | N | Y | Both | Short, ∼5 aa | |
FIGURE 6Structure of a Fabaceae albumin-1 cyclotide prepropeptide exemplified by Cter M. The linear Cter M precursor consists of the endoplasmic reticulum (ER) signal (red), the cyclotide domain (blue) which replaces the typical Fabaceae albumin-1 b-chain, the a-chain (yellow) and the C-terminal interlinker region (green). A specialized asparaginyl endopeptidease (AEP, butelase-1 (PDB code: 6DHI) effects head-to-tail cyclization of the Cter M domain of the precursor in planta and results in a mature CterM cyclotide (PDB code: 2LAM).